Market niche Intabio offers a Blaze system for real-time, intact protein isoform analysis, addressing high-throughput quality demands in biopharma development and manufacturing. Potential sales opportunities exist with biopharma companies seeking faster, more informative analytics to reduce development time and avoid costly missteps.

Technological edge Blaze combines separation, quantitation, and molecular identity with microfluidic and optional MS interfacing, enabling integrated analytics not readily available from standard platforms. Target prospects include labs needing streamlined workflows and direct peak identification to accelerate regulatory readiness.

Collaborative leverage Past collaboration with Bruker on UHR-QTOF interfaces and industry recognition in AB Sciex acquisition signals strategic credibility. Use this to approach instrument manufacturers, CROs, and contract developers who value proven interoperability and ecosystem partnerships.

Growth trajectory With funding history including Series A and B and a scrubbed revenue range of early-stage, Intabio appears poised for scaling. Sales opportunities exist with growing biopharma players needing scalable analytics solutions and potential expansion into adjacent biologics workflows.

Operational footprint Small team size (11-50 employees) and Newark, California base suggest a nimble, direct-sales approach. Focus on building high-touch, consultative engagements with decision-makers in development, QA, and manufacturing to accelerate pilots and accelerate time-to-value.